Adamis Pharmaceuticl (ADMP) 2.83 $ADMP
Adamis Pharmaceuticals Strengthens Patent Portfolio for its Dry Powder Inhaler
GlobeNewswire - Wed Aug 03, 8:00AM CDT
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company"
recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No. 14/622,617). The approved claims describe the device and components that are important for its drug delivery functions.
ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Announces $11.1 Million Registered Direct Offering
GlobeNewswire - Fri Jul 29, 7:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, and immunology, announced today that it has entered into definitive subscription agreements with investors pursuant to a registered direct offering for total gross proceeds of approximately $11.1 million. The closing of the transaction is expected to occur on August 2, 2016, subject to the satisfaction of customary closing conditions.
ADMP: 2.83 (+0.02)
Why is Adamis Pharmaceuticals (ADMP) Stock Crashing Today?
Madeleine Johnson - Zacks Investment Research - Mon Jun 06, 10:50AM CDT
On Monday, shares of Adamis Pharmaceuticals Corp. (ADMP) are crashing, down over 50% in morning trading after news broke that the Food and Drug Administration (FDA) sent the company a Complete Response Letter (CRL) about its New Drug Application of Epinephrine Pre-Filled Syringe.
ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
GlobeNewswire - Mon Jun 06, 5:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" announced that after the close of the stock markets on June 3, 2016 it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) product. PFS is for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction. A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form.
ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Announces License Agreement with Allergan plc Subsidiary for Epinephrine Pre-Filled Syringe
GlobeNewswire - Tue May 10, 5:48AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis" has entered into an exclusive licensing agreement with Allergan plc's wholly owned subsidiary, Watson Laboratories, Inc. ("Watson" , to commercialize Adamis' Epinephrine Pre-filled Syringe ("PFS" product candidate for the emergency treatment of anaphylaxis.
ADMP: 2.83 (+0.02), TEVA: 51.22 (+0.32)
Adamis Pharmaceuticals Completes Acquisition of US Compounding
GlobeNewswire - Tue Apr 12, 5:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis" announced today that it has successfully completed its previously announced acquisition (the "Acquisition" of US Compounding, Inc. ("USC" . Upon the closing of this transaction, USC has become a wholly-owned subsidiary of Adamis.
ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Announces Agreement to Acquire US Compounding
GlobeNewswire - Tue Mar 29, 5:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis" announced today that it has entered into a definitive merger agreement (the "Agreement" to acquire US Compounding, Inc. ("USC" , a privately held company registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act ("FD&C Act" , that provides prescription medications to patients, physician clinics, hospitals and surgery centers throughout most of the United States. Under the terms of the Agreement, upon the closing of the transactions contemplated by the Agreement USC will become a wholly-owned subsidiary of Adamis, all of the outstanding shares of USC will be converted into the right to receive approximately 1.62 million shares of Adamis common stock, and Adamis will assume certain secured debt obligations. The transaction is expected to close in the second quarter of 2016, subject to the satisfaction of customary closing conditions.
ADMP: 2.83 (+0.02)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), AVXL: 3.05 (+0.02), AMBX: (), ACH: 9.32 (+0.06), AMGN: 169.77 (-0.36), ADMP: 2.83 (+0.02), ABBV: 64.12 (+0.09)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), ARWR: 7.15 (+0.09), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), APTO: 2.20 (+0.16), AVXL: 3.05 (+0.02), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), ARRY: 3.50 (-0.02)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 11.52 (-0.26), ARWR: 7.15 (+0.09), AMBX: (), CLDX: 3.35 (-0.01), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), BIND: 0.78 (-0.09), BMY: 56.35 (-0.41), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), CORT: 5.31 (-0.04)
World Prostate Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5qnxq/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Prostate Cancer - Overview - Pipeline Products for Prostate Cancer - Comparative Analysis - Prostate Cancer - Therapeutics under Development by Companies - Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Prostate Cancer - Products under Development by Companies - Prostate Cancer - Products under Investigation by Universities/Institutes - Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - 35 of the 250 Companies - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Acino Pharma AG - Actinium Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - ADC Therapeutics Sarl - Aduro BioTech, Inc. - Advanced Cancer Therapeutics - Advantagene, Inc. - Advaxis, Inc. - Aeglea BioTherapeutics, Inc. - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Akshaya Bio Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - AnGes MG, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antisense Therapeutics Limited - Aphios Corporation - APIM Therapeutics AS - Aptose Biosciences Inc. - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/w5...ate_cancer
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), AMBX: (), ARQL: 1.40 (unch), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), APTO: 2.20 (+0.16), ATNM: 1.70 (-0.06), AVXL: 3.05 (+0.02), ABBV: 64.12 (+0.09)
Global Asthma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdlwml/asthma_pipeline) has announced the addition of the "Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Asthma Overview - Therapeutics Development - Pipeline Products for Asthma - Overview - Pipeline Products for Asthma - Comparative Analysis - Asthma - Therapeutics under Development by Companies - Asthma - Therapeutics under Investigation by Universities/Institutes - Asthma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Asthma - Products under Development by Companies - Asthma - Products under Investigation by Universities/Institutes - Asthma - Companies Involved in Therapeutics Development Companies Featured - Partial List - 4D Pharma Plc - AB Science SA - Abeome Corporation - Accolade Pharma LLC - Acorda Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - Afferent Pharmaceuticals, Inc. - AFFiRiS AG - Alba Therapeutics Corporation - ALK-Abello A/S - Allergopharma GmbH & Co. KG - Amakem NV - Amgen Inc. - AnaptysBio, Inc. - Antisense Therapeutics Limited - Aquinox Pharmaceuticals Inc. - ARA Healthcare Pvt. Ltd. - Ario Pharma Ltd - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Aurigene Discovery Technologies Limited - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Biokine Therapeutics Ltd. - BioLineRx, Ltd. - Bioncotech Therapeutics S.L. - Biotec Pharmacon ASA - BioTech Tools s.a. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - CalciMedica, Inc. For more information visit http://www.researchandmarkets.com/research/wd...a_pipeline
AQXP: 12.14 (-0.10), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), ACOR: 24.27 (-0.07), CLBS: 4.92 (+0.09), AZN: 33.31 (+0.71), ARRY: 3.50 (-0.02)
Adamis Pharmaceuticals enters into Series A-1 convertible preferred stock and warrants private placement
M2 - Wed Jan 27, 4:52AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) stated on Tuesday that it has received gross cash proceeds of approximately USD5m from the issuance of a private placement of 1,183,432 shares of Series A-1 convertible preferred stock to a fundamental healthcare institutional fund.
ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Announces Private Placement
GlobeNewswire - Tue Jan 26, 3:09PM CST
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis" announced today that it has completed a private placement financing transaction pursuant to which it issued 1,183,432 shares of Series A-1 Convertible Preferred Stock to a fundamental healthcare institutional fund, and received gross cash proceeds of approximately $5,000,000. The preferred stock is convertible into common stock at a conversion ratio of 1-to-1 at the option of the investor and has no preference to the common shares. The Company also issued to the investor warrants to purchase a number of shares of common stock or Series A1 Preferred equal to the number of shares of preferred stock purchased by the investor. The shares of Series A1 Preferred and warrants were sold in units, with each unit consisting of one share and one warrant, at a purchase price of $4.225 per unit. The warrants, which are exercisable for a period of five years, have an exercise price of $4.10 per share and are callable for cash.
ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals' resubmission of Epinephrine Pre-Filled Syringe NDA accepted by US FDA
M2 - Fri Jan 15, 5:46AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) said on Thursday that its New Drug Application (NDA) for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis has been accepted for review by the US Food and Drug Administration (FDA).
ADMP: 2.83 (+0.02)
Keratitis Pipeline Review, H2 2015
M2 - Wed Jan 06, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/ffh6vw/keratitis) has announced the addition of the "Keratitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Keratitis Overview - Therapeutics Development - Pipeline Products for Keratitis - Overview - Pipeline Products for Keratitis - Comparative Analysis - Keratitis - Therapeutics under Development by Companies - Keratitis - Therapeutics under Investigation by Universities/Institutes - Keratitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Keratitis - Products under Development by Companies - Keratitis - Products under Investigation by Universities/Institutes - Keratitis - Companies Involved in Therapeutics Development - Adamis Pharmaceuticals Corporation - Cellceutix Corporation - NanoViricides, Inc. - Peregrine Pharmaceuticals, Inc. - ReceptoPharm, Inc. - RegeneRx Biopharmaceuticals, Inc. - Sirnaomics, Inc. - The Medicines Company For more information visit http://www.researchandmarkets.com/research/ffh6vw/keratitis
ADMP: 2.83 (+0.02), NNVC: 1.51 (-0.03)
Chlamydia Infections Pipeline Review, H2 2015 - Analysis, Trends, Technologies & Forecasts
M2 - Thu Dec 17, 3:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/6dz7mn/chlamydia) has announced the addition of the "Chlamydia Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chlamydia Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Abera Bioscience AB - Adamis Pharmaceuticals Corporation - Big DNA Ltd. - CEL-SCI Corporation - Folia Biotech Inc. - Genocea Biosciences, Inc. - Merck & Co., Inc. - Osel Inc. - Prokarium Limited - QureTech Bio AB - Selecta Biosciences, Inc. - SIGA Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/6dz7mn/chlamydia
CVM: 0.43 (-0.05), MRK: 62.98 (+0.08), ADMP: 2.83 (+0.02), GNCA: 5.37 (+0.09)
World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 11.52 (-0.26), EBS: 26.90 (+0.49), ARWR: 7.15 (+0.09), AMBX: (), PFE: 34.77 (+0.09), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), BIND: 0.78 (-0.09), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), MDVN: 80.85 (-0.08), PGNX: 5.96 (-0.18), GTXI: 0.57 (unch), AZN: 33.31 (+0.71), NLNK: 9.91 (-0.40), ABBV: 64.12 (+0.09)
Adamis Pharmaceuticals resubmits Epinephrine Pre-Filled Syringe's NDA to the US FDA
M2 - Tue Dec 08, 5:46AM CST
Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) said on Monday that it has refiled its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis.
ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Strengthens Patent Portfolio for its Dry Powder Inhaler
GlobeNewswire - Wed Aug 03, 8:00AM CDT
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company"
recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No. 14/622,617). The approved claims describe the device and components that are important for its drug delivery functions. ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Announces $11.1 Million Registered Direct Offering
GlobeNewswire - Fri Jul 29, 7:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, and immunology, announced today that it has entered into definitive subscription agreements with investors pursuant to a registered direct offering for total gross proceeds of approximately $11.1 million. The closing of the transaction is expected to occur on August 2, 2016, subject to the satisfaction of customary closing conditions.
ADMP: 2.83 (+0.02)
Why is Adamis Pharmaceuticals (ADMP) Stock Crashing Today?
Madeleine Johnson - Zacks Investment Research - Mon Jun 06, 10:50AM CDT
On Monday, shares of Adamis Pharmaceuticals Corp. (ADMP) are crashing, down over 50% in morning trading after news broke that the Food and Drug Administration (FDA) sent the company a Complete Response Letter (CRL) about its New Drug Application of Epinephrine Pre-Filled Syringe.
ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
GlobeNewswire - Mon Jun 06, 5:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company"
announced that after the close of the stock markets on June 3, 2016 it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) product. PFS is for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction. A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form. ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Announces License Agreement with Allergan plc Subsidiary for Epinephrine Pre-Filled Syringe
GlobeNewswire - Tue May 10, 5:48AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis"
has entered into an exclusive licensing agreement with Allergan plc's wholly owned subsidiary, Watson Laboratories, Inc. ("Watson" , to commercialize Adamis' Epinephrine Pre-filled Syringe ("PFS" product candidate for the emergency treatment of anaphylaxis. ADMP: 2.83 (+0.02), TEVA: 51.22 (+0.32)
Adamis Pharmaceuticals Completes Acquisition of US Compounding
GlobeNewswire - Tue Apr 12, 5:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis"
announced today that it has successfully completed its previously announced acquisition (the "Acquisition" of US Compounding, Inc. ("USC" . Upon the closing of this transaction, USC has become a wholly-owned subsidiary of Adamis. ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Announces Agreement to Acquire US Compounding
GlobeNewswire - Tue Mar 29, 5:45AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis"
announced today that it has entered into a definitive merger agreement (the "Agreement" to acquire US Compounding, Inc. ("USC" , a privately held company registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act ("FD&C Act" , that provides prescription medications to patients, physician clinics, hospitals and surgery centers throughout most of the United States. Under the terms of the Agreement, upon the closing of the transactions contemplated by the Agreement USC will become a wholly-owned subsidiary of Adamis, all of the outstanding shares of USC will be converted into the right to receive approximately 1.62 million shares of Adamis common stock, and Adamis will assume certain secured debt obligations. The transaction is expected to close in the second quarter of 2016, subject to the satisfaction of customary closing conditions. ADMP: 2.83 (+0.02)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), AVXL: 3.05 (+0.02), AMBX: (), ACH: 9.32 (+0.06), AMGN: 169.77 (-0.36), ADMP: 2.83 (+0.02), ABBV: 64.12 (+0.09)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), ARWR: 7.15 (+0.09), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), APTO: 2.20 (+0.16), AVXL: 3.05 (+0.02), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), ARRY: 3.50 (-0.02)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 11.52 (-0.26), ARWR: 7.15 (+0.09), AMBX: (), CLDX: 3.35 (-0.01), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), BIND: 0.78 (-0.09), BMY: 56.35 (-0.41), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), CORT: 5.31 (-0.04)
World Prostate Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5qnxq/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Prostate Cancer - Overview - Pipeline Products for Prostate Cancer - Comparative Analysis - Prostate Cancer - Therapeutics under Development by Companies - Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Prostate Cancer - Products under Development by Companies - Prostate Cancer - Products under Investigation by Universities/Institutes - Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - 35 of the 250 Companies - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Acino Pharma AG - Actinium Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - ADC Therapeutics Sarl - Aduro BioTech, Inc. - Advanced Cancer Therapeutics - Advantagene, Inc. - Advaxis, Inc. - Aeglea BioTherapeutics, Inc. - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Akshaya Bio Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - AnGes MG, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antisense Therapeutics Limited - Aphios Corporation - APIM Therapeutics AS - Aptose Biosciences Inc. - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/w5...ate_cancer
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), AMBX: (), ARQL: 1.40 (unch), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), APTO: 2.20 (+0.16), ATNM: 1.70 (-0.06), AVXL: 3.05 (+0.02), ABBV: 64.12 (+0.09)
Global Asthma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdlwml/asthma_pipeline) has announced the addition of the "Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Asthma Overview - Therapeutics Development - Pipeline Products for Asthma - Overview - Pipeline Products for Asthma - Comparative Analysis - Asthma - Therapeutics under Development by Companies - Asthma - Therapeutics under Investigation by Universities/Institutes - Asthma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Asthma - Products under Development by Companies - Asthma - Products under Investigation by Universities/Institutes - Asthma - Companies Involved in Therapeutics Development Companies Featured - Partial List - 4D Pharma Plc - AB Science SA - Abeome Corporation - Accolade Pharma LLC - Acorda Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - Afferent Pharmaceuticals, Inc. - AFFiRiS AG - Alba Therapeutics Corporation - ALK-Abello A/S - Allergopharma GmbH & Co. KG - Amakem NV - Amgen Inc. - AnaptysBio, Inc. - Antisense Therapeutics Limited - Aquinox Pharmaceuticals Inc. - ARA Healthcare Pvt. Ltd. - Ario Pharma Ltd - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Aurigene Discovery Technologies Limited - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Biokine Therapeutics Ltd. - BioLineRx, Ltd. - Bioncotech Therapeutics S.L. - Biotec Pharmacon ASA - BioTech Tools s.a. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - CalciMedica, Inc. For more information visit http://www.researchandmarkets.com/research/wd...a_pipeline
AQXP: 12.14 (-0.10), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), ACOR: 24.27 (-0.07), CLBS: 4.92 (+0.09), AZN: 33.31 (+0.71), ARRY: 3.50 (-0.02)
Adamis Pharmaceuticals enters into Series A-1 convertible preferred stock and warrants private placement
M2 - Wed Jan 27, 4:52AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) stated on Tuesday that it has received gross cash proceeds of approximately USD5m from the issuance of a private placement of 1,183,432 shares of Series A-1 convertible preferred stock to a fundamental healthcare institutional fund.
ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals Announces Private Placement
GlobeNewswire - Tue Jan 26, 3:09PM CST
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company" or "Adamis"
announced today that it has completed a private placement financing transaction pursuant to which it issued 1,183,432 shares of Series A-1 Convertible Preferred Stock to a fundamental healthcare institutional fund, and received gross cash proceeds of approximately $5,000,000. The preferred stock is convertible into common stock at a conversion ratio of 1-to-1 at the option of the investor and has no preference to the common shares. The Company also issued to the investor warrants to purchase a number of shares of common stock or Series A1 Preferred equal to the number of shares of preferred stock purchased by the investor. The shares of Series A1 Preferred and warrants were sold in units, with each unit consisting of one share and one warrant, at a purchase price of $4.225 per unit. The warrants, which are exercisable for a period of five years, have an exercise price of $4.10 per share and are callable for cash. ADMP: 2.83 (+0.02)
Adamis Pharmaceuticals' resubmission of Epinephrine Pre-Filled Syringe NDA accepted by US FDA
M2 - Fri Jan 15, 5:46AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) said on Thursday that its New Drug Application (NDA) for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis has been accepted for review by the US Food and Drug Administration (FDA).
ADMP: 2.83 (+0.02)
Keratitis Pipeline Review, H2 2015
M2 - Wed Jan 06, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/ffh6vw/keratitis) has announced the addition of the "Keratitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Keratitis Overview - Therapeutics Development - Pipeline Products for Keratitis - Overview - Pipeline Products for Keratitis - Comparative Analysis - Keratitis - Therapeutics under Development by Companies - Keratitis - Therapeutics under Investigation by Universities/Institutes - Keratitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Keratitis - Products under Development by Companies - Keratitis - Products under Investigation by Universities/Institutes - Keratitis - Companies Involved in Therapeutics Development - Adamis Pharmaceuticals Corporation - Cellceutix Corporation - NanoViricides, Inc. - Peregrine Pharmaceuticals, Inc. - ReceptoPharm, Inc. - RegeneRx Biopharmaceuticals, Inc. - Sirnaomics, Inc. - The Medicines Company For more information visit http://www.researchandmarkets.com/research/ffh6vw/keratitis
ADMP: 2.83 (+0.02), NNVC: 1.51 (-0.03)
Chlamydia Infections Pipeline Review, H2 2015 - Analysis, Trends, Technologies & Forecasts
M2 - Thu Dec 17, 3:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/6dz7mn/chlamydia) has announced the addition of the "Chlamydia Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chlamydia Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Abera Bioscience AB - Adamis Pharmaceuticals Corporation - Big DNA Ltd. - CEL-SCI Corporation - Folia Biotech Inc. - Genocea Biosciences, Inc. - Merck & Co., Inc. - Osel Inc. - Prokarium Limited - QureTech Bio AB - Selecta Biosciences, Inc. - SIGA Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/6dz7mn/chlamydia
CVM: 0.43 (-0.05), MRK: 62.98 (+0.08), ADMP: 2.83 (+0.02), GNCA: 5.37 (+0.09)
World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 11.52 (-0.26), EBS: 26.90 (+0.49), ARWR: 7.15 (+0.09), AMBX: (), PFE: 34.77 (+0.09), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), BIND: 0.78 (-0.09), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), MDVN: 80.85 (-0.08), PGNX: 5.96 (-0.18), GTXI: 0.57 (unch), AZN: 33.31 (+0.71), NLNK: 9.91 (-0.40), ABBV: 64.12 (+0.09)
Adamis Pharmaceuticals resubmits Epinephrine Pre-Filled Syringe's NDA to the US FDA
M2 - Tue Dec 08, 5:46AM CST
Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) said on Monday that it has refiled its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis.
ADMP: 2.83 (+0.02)
